|Description||development of novel therapeutics|
|Seed, 10/2006 |
Hokkaido Venture Capital
Tacere Therapeutics, Inc. specializes in the development of novel therapeutics for the treatment of serious infectious diseases such as Hepatitis C (HCV). Combining expertise in RNA interference (RNAi), gene medicine, and novel biologicals, Tacere possesses proprietary skill in the identification and development of RNAi therapeutics.